Repro Med Systems upgraded by Piper Sandler with a new price target
$KRMD
Medical/Dental Instruments
Health Care
Piper Sandler upgraded Repro Med Systems from Neutral to Overweight and set a new price target of $3.50 from $3.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2024 | $4.00 | Buy | B. Riley Securities |
| 9/7/2023 | $4.00 | Buy | Lake Street |
| 9/7/2023 | $4.50 | Buy | B. Riley Securities |
| 11/10/2022 | $3.00 → $4.00 | Hold → Buy | Canaccord Genuity |
| 11/10/2022 | $3.00 → $3.50 | Neutral → Overweight | Piper Sandler |
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximatel
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 and raised full year 2024 revenue and gross margin guidance. Financial Highlights Second quarter 2024 net revenues of $8.4 million, a 22% increase over the prior year with record-high quarterly revenues Core business (U.S. and International) growth of 20% over the prior year driven by overall SCIg market growth, share gains, and geographic expansion Gross
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 7, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences. KORU Medical's management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19th, 2024. KORU Medical's management team will also be participating at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21st, 2024. About KORU Medical Systems KORU Medical deve
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large-volume subcutaneous infusion solutions, this week presented data demonstrating nursing preference for the use of the KORU FreedomEdge® Infusion System to administer subcutaneous oncology infusions in the clinic setting. The results of the case study were presented at the PODD 2024 Conference on October 28, 2024, in Boston, Massachusetts. The objective of the Nursing Preference Study was to assess time spent with patients, impact on nursing and patient comfort, and overall nurse p
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
B. Riley Securities initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.50
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the promotion of Christopher Pazdan, to Chief Operating Officer, effective July 18, 2024. Mr. Pazdan has been with the organization since 2021, and last served as the Company's Senior Vice President of Operations overseeing Quality, Regulatory, Operations, Supply Chain and Project Management. In his role as COO, Chris will also oversee the Research and Development organization and be responsible for the Company's product d
The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the "Freedom System") and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC® prefillable polymer syringes (PFS), intend to collaborate on optimization of drug delivery in the large volume subcutaneous infusion market.When combined with pharma therapies, the joint offering will optimize the ability to administer large volumes of medication subcutaneously and streamline the pharmaceutical drug development process.Application of these technologies provide the potential to simplify and de-risk delivery of large volume subcutaneous therapies in both administration by healthcare professionals in a clini